ArticleContraception2026
Patterns of hormonal contraception use in women with sickle cell disease and employer-sponsored insurance.
Article in Contraception, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectiveWhile an improved understanding of the epidemiology and outcomes of hormonal contraceptive use in persons with sickle cell disease is needed to better inform evidence-based guidelines, patterns of contraception use remain understudied. Our objective was to examine patterns of contraception use among patients with sickle cell disease and employer-sponsored insurance. STUDY
designOur analyses utilized the Merative™ MarketScan® Commercial Database (2012-2019). The study included females 12-44 years meeting the study definition of sickle cell disease (presence of three ICD-9 or ICD-10 codes consistent with sickle cell disease). We utilized pharmacy and procedure claims to capture hormonal contraception use.
resultsWe identified 5957 unique females of reproductive age (12-44 years) with sickle cell disease, 1653 (28%) of whom utilized hormonal contraception. When examining the first identified contraception prescription, 43.9% were prescribed estrogen-containing agents and 56.1% were prescribed progestin-only. The most frequently prescribed contraceptive was combined contraceptive pills (n = 645, 39%), followed by depot medroxyprogesterone acetate (n = 413, 25%). Intrauterine devices and subcutaneous implants were prescribed to 15.7% and 6.4% of individuals, respectively.
conclusionsOur work identified hormonal contraception use in less than one-third of reproductive-age females with sickle cell disease using employer-sponsored insurance. Over 40% of new users of hormonal contraception received prescriptions for estrogen-containing agents, demonstrating a need for education regarding the 2024 U.S. MEC recommendations, which contradict estrogen for patients with sickle cell disease. Future directions should also include understanding patient characteristics and health outcomes among combined hormonal contraceptive users with sickle cell disease to better inform eligibility criteria. IMPLICATIONS: Estrogen-containing agents make up a substantial percentage of contraception prescriptions in women with sickle cell disease and employer-sponsored insurance. High-quality data regarding the safety of hormonal contraception in the setting of sickle cell disease are needed to inform evidence-based guidelines and medical eligibility criteria.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.